Revier Therapeutics

Revier Therapeutics is a biotech company advancing disease-modifying therapies for patients with cardiometabolic disease. The company has established a therapeutic approach to selectively target class IIa HDACs, developing orally available small molecules designed to inhibit the pathogenic enzymatic activity of these enzymes while preserving healthy biological function and avoiding canonical HDAC inhibition. Revier is advancing a pipeline of novel disease modulators starting with heart failure with preserved ejection fraction (HFpEF) and atherosclerotic cardiovascular disease (ASCVD) as its initial indications; the company notes that 30 million people live with HFpEF worldwide and that 500 million people are affected by ASCVD-related conditions, including coronary artery disease and ischemic stroke. Revier Therapeutics GmbH is based in Heidelberg, Germany, and launched with a €6 Million seed financing to pioneer class IIa HDAC inhibitors for cardiometabolic disease.